Statin Therapy Worsens Insulin Sensitivity in Women With Polycystic Ovary Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study

Puurunen, Johanna; Piltonen, Terhi; Puukka, Katri; Ruokonen, Aimo; Savolainen, Markku J.; Bloigu, Risto; Morin‐Papunen, Laure; Tapanainen, Juha S.

doi:10.1210/jc.2013-2674

Cited by 89 publications

(95 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there is evidence that statins can suppress inflammation(37), they also appear to modestly increase risk of diabetes(38), potentially through decrease in insulin sensitivity. In a small, randomized trial of otherwise healthy women with polycystic ovarian disease, the group treated with atorvastatin was found to have a significant decrease in C reactive protein (CRP), but also a significant decrease in insulin sensitivity compared to women who received placebo(39). It is plausible that statins exert the same effect on BC survivors who are treated with chemotherapy and this counteracts the positive effect statins have on obesity-associated inflammation.…”

Section: Discussionmentioning

confidence: 99%

Weight Change in Breast Cancer Survivors Compared to Cancer-Free Women: A Prospective Study in Women at Familial Risk of Breast Cancer

Gross

May

Axilbund

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background This study prospectively examines weight gain in breast cancer (BC) survivors compared to cancer-free women from a familial risk cohort. Methods Absolute and percent weight change over 4 years was compared among 303 BC survivors and 307 cancer-free women matched on age and menopausal status, from the same familial risk cohort. Linear and logistic regression was used to estimate the association between survivor status and weight gain. Results Overall, BC survivors gained significantly more weight (β = 3.06 pounds, 95% confidence interval (CI) 0.94, 5.17) than cancer-free women. Significant weight gain was observed in survivors diagnosed less than 5 years prior to baseline (β = 3.81 pounds, 95% CI 1.22, 6.29) and women with estrogen receptor (ER) negative tumors (β = 7.26 pounds, 95% CI 2.23, 12.30). Further, survivors treated with chemotherapy were 2.1 times more likely to gain at least 11 pounds during follow-up compared to cancer-free women (OR = 2.10, 95% CI 1.21, 3.63). Weight gain was even greater among survivors who took statins while undergoing chemotherapy treatment (p for interaction = 0.01). Conclusion This is the first study to demonstrate that weight gain is an important issue in BC survivors with a familial risk; further, that in the first five years post-treatment, BC survivors gain weight at a faster rate than cancer-free women, particularly after chemotherapy and statin use but not after hormone therapy alone. Impact Our findings provide support for the development of weight gain interventions for young BC survivors with a familial risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Weight Change in Breast Cancer Survivors Compared to Cancer-Free Women: A Prospective Study in Women at Familial Risk of Breast Cancer

Gross

May

Axilbund

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…The absolute risk for cardiovascular events in young women is low and treatment with statins is rarely indicated in reproductive-aged women with PCOS. In recent studies, simvastatin decreased androgen levels (38), but was associated with increased insulin resistance (39). There are insufficient safety data on treatment with statins during pregnancy.…”

Section: Cardiometabolic Disease In Pcosmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome

Glintborg

Andersen

2017

European Journal of Endocrinology

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most prevalent endocrine condition in premenopausal women. The syndrome is characterized by hyperandrogenism, irregular menses and polycystic ovaries when other etiologies are excluded. Obesity, insulin resistance and low vitamin D levels are present in more than 50% patients with PCOS, these factors along with hyperandrogenism could have adverse effects on long-term health. Hyperinflammation and impaired epithelial function were reported to a larger extent in women with PCOS and could particularly be associated with hyperandrogenism, obesity and insulin resistance. Available data from register-based and data linkage studies support that metabolic-vascular and thyroid diseases, asthma, migraine, depression and cancer are diagnosed more frequently in PCOS, whereas fracture risk is decreased. Drug prescriptions are significantly more common in PCOS than controls within all diagnose categories including antibiotics. The causal relationship between PCOS and autoimmune disease represents an interesting new area of research. PCOS is a lifelong condition and long-term morbidity could be worsened by obesity, sedentary way of life, Western-style diet and smoking, whereas lifestyle intervention including weight loss may partly or fully resolve the symptoms of PCOS and could improve the long-term prognosis. In this review, the possible implications of increased morbidity for the clinical and biochemical evaluation of patients with PCOS at diagnosis and follow-up is further discussed along with possible modifying effects of medical treatment.

show abstract

“…PCOS is associated with several other metabolic and endocrinological disorders such as anovulatory infertility, obesity, insulin resistance and type 2 diabetes . Women with PCOS show many features similar to metabolic syndrome, including dysfunction of the hypothalamic‐pituitary‐adrenal (HPA) axis, hyperinsulinaemia, increase in cytokines and dyslipidaemia . Although insulin resistance is not required for the diagnosis of PCOS, it is crucial in the development of PCOS.…”

Section: Introductionmentioning

confidence: 99%

Abnormal irisin level in serum and endometrium is associated with metabolic dysfunction in polycystic ovary syndrome patients

Wang

Guo

Zhang

et al. 2018

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

Statin Therapy Worsens Insulin Sensitivity in Women With Polycystic Ovary Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study

Cited by 89 publications

References 37 publications

Weight Change in Breast Cancer Survivors Compared to Cancer-Free Women: A Prospective Study in Women at Familial Risk of Breast Cancer

Weight Change in Breast Cancer Survivors Compared to Cancer-Free Women: A Prospective Study in Women at Familial Risk of Breast Cancer

MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome

Abnormal irisin level in serum and endometrium is associated with metabolic dysfunction in polycystic ovary syndrome patients

Contact Info

Product

Resources

About